

Study of Serum Pepsinogen 1 and Pepsinogen 1 to Pepsinogen 2 Ratio Level as a Screening for Atrophic Gastritis and Gastric Cancer

Abozamel MSEM^{*}, Shamsya AM¹, Hesien WM¹, Ayad MW² and Elbanna AA¹

¹Department of Internal Medicine, Faculty of Medicine, Alexandria University, Egypt

²Department of Clinical Pathology, Faculty of Medicine, Alexandria University, Egypt

*Corresponding author:

Mohammed salah eldien Metwaly Abozamel,
Department of Internal Medicine, Faculty of Medicine,
Alexandria University, Egypt, Tel: 201007095659;
E-mail: medodoctor25@yahoo.com

Received: 20 Mar 2023

Accepted: 26 Apr 2023

Published: 03 May 2023

J Short Name: JJGH

Copyright:

©2023 Abozamel MSEM This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and build upon your work non-commercially.

Citation:

Abozamel MSEM. Study of Serum Pepsinogen 1 and Pepsinogen 1 to Pepsinogen 2 Ratio Level as a Screening for Atrophic Gastritis and Gastric Cancer. J Gastro Hepato. 2023; V9(19): 1-7

Keywords:

Serum pepsinogen; Gastric cancer; Atrophic gastritis

1. Abstract

1.1. Objective: To evaluate pepsinogen 1 (Pg 1) level in serum and pepsinogen 1 to pepsinogen 2 ratio (Pg 1/2) in patients with AG and GC and compare them to gold standard endoscopic examination in those patients, to detect the sensitivity and specificity of these markers to evaluate their value as a future seromarker or tumor marker.

1.2. Patients and Method: This was an observational case-control comparative study that included 60 patients diagnosed with atrophic gastritis and gastric carcinoma. A clinical and endoscopic examination were used to make the diagnosis, and gastric biopsies were examined histologically to confirm it. Two separate groups of patients were formed, with 30 patients involved within group 1 having AG and 30 patients in group 2 having GC. As a control group, 30 healthy volunteers were enlisted. Informed written consent will be taken from all patients.

1.3. Results: Serum Pg 1 and Pg 1/2 in AG and GC patients were comparable ($p = .098, 0.976$, respectively), however, compared to healthy controls, they were statistically considerably lower ($p < 0.001$ for all). The optimum cut-off values for diagnosing AG or GC were Pg 1 18.96 and Pg 1/2 2.25; these values may produce a 100% sensitivity (94-100), 100% specificity (88.4-100), positive predictive value (PPV) that was 100%, and 100% negative predictive value (NPV).

1.4. Conclusion: For AG and GC diagnosis, serum Pg exhibited a very high diagnostic value.

2. Introduction

Gastric cancer (GC) was discovered to be the fourth most prevalent cancer-related death factor [1, 2]. However, if it is discovered from

the early lesions that are likely to be precancerous, such as atrophic gastritis, a common progressive illness, It has a great prognosis and is treatable [3, 4].

When it comes to high-risk GC conditions, atrophic gastritis (AG) can progress from modest lesions at first to moderate and severe ones [5]. Therefore, it is essential to carry out early detection of the high-risk group suffering moderate and severe AG related lesions in order to lower the risk of GC. However, these AG related lesions are most probably asymptomatic in populations, making it hard to be detected with recommended current methods like guided biopsies or endoscopy. In order to screen programs for AG lesions, non-invasive techniques are now required [3, 4].

As a result of the stomach lumen's acidic pH, pepsinogen (Pg), a proenzyme that is abundantly released by the gastric mucosal cells, is transformed into pepsin. There are two Pg immunological categories: Pg 1 and also Pg 2. Additionally, the pepsinogen ratio Pg 1/2 was calculated [6]. Approximately, One percent of the pepsinogens produced into the stomach lumen are able to enter the bloodstream and are subsequently found in the serum. By using serum Pg levels, this technique enables investigation of the morphological and functional state of the stomach mucosa. Atrophy of the mucosal glands in the antrum and/or corpus lowers the Pg I/II ratio and influences Pg 1 and Pg 2 levels [7].

Currently, Pg has been found to be the most reliable non-invasive biomarker for the diagnosis of severe AG or GC [8-11]. However, its application is still controversial [12, 13], and it is advised to utilize it carefully and with caution [8] since the populations' cut-off values vary [11, 14].

Accordingly, we aimed to evaluate serum Pg 1 and Pg 1/2 in patients with AG and GC and compare them to gold standard endoscopic examination in those patients, to detect the sensitivity and specificity of these markers to evaluate their value as a future seromarker or tumor marker.

2.1. Patients Involved and Methods Used

This case-control observational study included 60 adults over the age of 18 with GC and AG. Clinical and endoscopic evidence supported the diagnosis, which was then supported by a histological review of gastric biopsies. Patients were chosen from outpatient clinics and were scheduled for upper GIT Endoscopy in Endoscopy unit in Gastroenterology Unit in Internal Medicine Department, Alexandria University Hospital. After clearly informing all patients, their written consent was obtained. There were two groups of patients: group 1, which contained 30 AG diagnosed patients, and group 2, which had 30 patients with GC. 30 healthy people were enlisted as a control group.

Patients who had undergone partial or total gastrectomy, patients who were undergoing chemotherapy or radiotherapy, patients with gastric polyps, patients suffering gastric lymphoma, and patients suffering gastric carcinoid were all excluded from the study. Patients who had taken inhibitors of proton pump or nonsteroidal anti-inflammatory medicines within the earlier six weeks before enrolment were also excluded.

Each patient underwent a full medical history review as well as a regional and local clinical abdominal examination. All patients underwent upper gastrointestinal endoscopy using traditional and narrow band imaging endoscopy with biopsy. Biopsy samples were collected using the most recent Sydney system of classification [15]. Five biopsy samples were obtained: Two were taken from the antrum, which is 2 to 3 cm from the pylorus; one was taken from the lesser distal curvature, and the other from the greater distal curvature; two were taken from the corpus, which is 8 cm away from the cardia; one was taken from the lesser curvature; and one was taken from the incisura angularis. Classification of AG using the Sydney system of grading [15]. Serum Pg 1 and Pg 2 assay was estimated by Enzyme-linked immunosorbent assay (ELISA) and Pg 1/2 was calculated. Finally, Pylori Antibodies IgG in blood and Pylori Ag in the stool were assessed.

3. Results

Table 1 represents patients' demographic data and H. Pylori tests findings. When compared to controls, Pg 1 and Pg1/2 were both lower significantly among the group diagnosed with AG and GC group ($p < 0.001$ for all), according to statistical analysis. In contrast, there was difference of no statistical significance in Pg 1 and Pg1/2 among the AG group and the GC group ($p = .098, 0.976$, respectively) (Table 2).

The Sydney classification found that antrum AG was reported in 10 patients (33.33%), with mild gastritis being described in two patients

(20%), moderate gastritis in four patients (40%), and severe gastritis in four patients (40%). Corpus AG was detected in 6 patients (20%), distributed as mild, moderate, and severe AG in one patient (16.67%), three patients (50%), and two patients (33.33%) respectively. Multifocal AG was seen in 14 patients (46.67%), distributed as mild gastritis in three patients (21.43%) moderate gastritis in six patients (42.86%), and severe gastritis in five patients (35.71%).

In terms of Pg1 and Pg1/2, there was difference that was not significant statistically between males and females with p -values = 0.383 and 0.623, respectively). Regarding Pg1 and Pg1/2, there was a difference that was statistically not significant among H. pylori positive and also negative individuals ($p = 0.633$ and $p = 0.331$, respectively). (Table 3) Pg1 levels were statistically higher in patients with severe exercise than in those with low and moderate activity ($p = 0.001$ and $p = 0.001$, respectively) Pg1/2 was statistically significantly lower in patients with severe activity compared to those with light and moderate activity levels ($p = 0.017$ and $p = 0.023$, respectively). However, there was no statistically significant difference in the Pg1/2 and Pg1 ratios between patients who exercised lightly and moderately ($p = 0.278$ and 0.58, respectively) (Table 3).

In AG patients, Pg1 and age had a statistically significant high negative correlation ($r = -0.806, p < 0.001$) (Figure 1). In contrast, the Pg1/2 ratio and age did not have a statistically significant relation among AG patients ($r = -0.304, p = 0.102$).

According to histological examination, gastric adenocarcinoma was categorized into two types; intestinal type in 22 patients (73.33%) and diffuse type in 8 patients (26.67%). According to location, gastric cancer was found in the antrum within 14 patients (46.67%), body within 7 patients (23.33%), fundus within 4 patients (13.33%), cardia in 3 patients (10%), and pylorus in two patients (6.67%).

In terms of Pg1 and Pg1/2, there was difference of no statistical significance among both the males and the females with p -values = 0.154 and 0.95, respectively. Regarding Pg1 and Pg1/2, there was no significant difference statistically among both H. pylori positive and negative individuals ($p = 0.4$ and $p = 0.92$, respectively) (Table 4).

In GC patients, there was high significant negative connection statistically between Pg1 and age. ($r = -0.95, p < 0.001$) (Figure 2). In contrast, the Pg1/2 ratio and age did not have a correlation of statistical significance in GC patients ($r = -0.133, p = 0.48$).

Overall model including (age, sex, H. pylori, and disease) is statistically significant in predicting Pg1 and Pg1/2 ratio as ($F = 1486.88, p < 0.001$), The model explains 98.5 percent of the Pg1 variability and ($F = 1724.448, p < 0.001$), model explains (99%) of Pg1/2 ratio variability (Table 5).

Table 6 shows the ROC curve analysis of Pg 1 and Pg1/2 ratio. It shows that pg1 (ng/l) can significantly discriminate between patients having AG or GC and healthy individuals as diagnostic accuracy ((AUC) = 1.00 (95% CI), $p < 0.001$), as cut of point which has highest sensitivity, specificity ≤ 18.96 (sensitivity = 100, specificity = 100).

Also, Pg1/2 ratio (ng/l) can significantly discriminate between patients having AG or GC and healthy individuals as diagnostic accuracy ((AUC) = 1.00 (95% CI), $p < 0.001$), as cut of point which has highest sensitivity, specificity ≤ 2.25 (sensitivity = 100, specificity = 100).

Table 1: Comparison of the three study groups based on demographic parameters.

Sociodemographic data	Atrophic gastritis (n=30)		Gastric cancer (n= 30)		Controls (n= 30)		Test of significance (p)
	No.	%	No.	%	No.	%	
Sex							
Male	16	53.3	16	53.3	15	50	$\chi^2 = 0.089,$
Female	14	46.7	14	46.7	15	50	$p = 0.956$
Age (years)							
Mean \pm SD	49.47 \pm 10.56		58.23 \pm 9.25		50.17 \pm 11.82		F= 6.342, $p = 0.003^*$
Median (Min – Max)	49.5 (34 – 66)		55.5 (45 – 77)		48.0 (33 – 69)		
Significance bet. groups	p1= 0.005*, p2= 0.965, p3= 0.011*						
H. pylori:							
Negative	15	50	16	53.3	14	46.7	$\chi^2 = 0.267,$
Positive	15	50	14	46.7	16	53.3	$p = 0.875$

χ^2 ; Chi-square test to compare the three involved study groups

F; One-Way ANOVA test, pairwise comparison was done using Tukey test p1;

p value between atrophic gastritis and gastric cancer

p²; p value between atrophic gastritis and controls

p³; p value between gastric cancer and controls.

SD; standard deviation, * significant ($p < 0.05$)

Table 2: Comparison of the Pg1 and Pg1/2 ratio biomarkers among the three involved study groups

	Atrophic gastritis (n=30)	Gastric cancer (n= 30)	Controls (n= 60)	Test of significance (p)
Pg 1 (ng/ml)				
Mean \pm SD	16.95 \pm 1.12	17.83 \pm 0.85	47.23 \pm 3.69	H= 63.900, $p < 0.001^*$
Median (Min – Max)	16.3(15.74-18.84)	17.9 (16.14-18.9)	47.4 (41.28-52.14)	
Significance bet. Groups	p1= .098, p2< 0.001*, p3< 0.001*			
Pg1/2 (ng/ml)				
Mean \pm SD	2.02 \pm 0.08	2.05 \pm 0.07	4.53 \pm 0.32	H= 60.308, $p < 0.001^*$
Median (Min – Max)	2.02 (1.89 - 2.25)	2.05 (1.91 - 2.21)	4.52 (4.01 - 5.12)	
Significance bet. Groups	p1= 0.976, p2< 0.001*, p3< 0.001*			

H; Kruskal Wallis test, pairwise comparison was done using Bonferroni test

p1; p value between atrophic gastritis and gastric cancer

p2; p value between atrophic gastritis and controls

p3; p value between gastric cancer and controls.

SD; standard deviation, * significant ($p < 0.05$)

Table 3: Distribution of Pg1 and Pg1/2 ratio with different variables among AG patients.

Variables	Pg1 (ng/ml)		Test of significance (p)	Pg1/2 ratio (ng/ml)		Test of significance (p)
	Mean \pm SD	Median (Min- Max)		Mean \pm SD	Median (Min- Max)	
Sex						
Male	16.79 \pm 1.12	16.17 (15.75-18.84)	U= 91.0	2.0 \pm 0.08	2.02 (1.9-2.18)	t= -0.497
Female	17.12 \pm 1.13	16.74 (15.74-18.66)	p= 0.383	2.03 \pm 0.09	2.02 (1.89-2.25)	p= 0.623
H. pylori						
Positive	17.01 \pm 1.19	16.24 (15.88-18.84)	U= 101.0	2.0 \pm 0.07	2.02 (1.89-2.18)	t= -0.990
Negative	16.88 \pm 1.08	16.44 (15.74-18.52)	p= 0.633	2.03 \pm 0.09	2.02 (1.92-2.25)	p= 0.331

Activity						
Mild	18.45 ± 0.23	18.47 (18.2-18.84)	H= 23.055 p< 0.001*	2.07 ± 0.09	2.04 (2.0-2.25)	H= 7.566 p= 0.023*
Moderate	17.11 ± 0.93	17.06 (16.11-18.66)		2.04 ± 0.07	2.02 (1.94-2.18)	
Severe	15.92 ± 0.12	15.95 (15.74-16.1)		1.96 ± 0.06	1.95 (1.89-2.03)	
Significant bet. groups	p1= 0.278, p2< 0.001*, p3= 0.001*			p1= 0.58, p2< 0.017*, p3=0.023*		

U; Mann-Whitney test, t; independent t test

H; Kruskal Wallis test, pairwise comparison was done using Bonferroni test p1; p value between mild and moderate

p2; p value between mild and severe

p3; p value between moderate and severe. SD; standard deviation, * significant (p<0.05)




Figure 1: Correlation between Pg1 and age among AG group

Table 4: Both Pg1 and Pg1/2 ratio distribution among the GC group according to sociodemographic traits.

Variables	Pg1 (ng/ml)		Test of significance (p)	Pg1/2 ratio (ng/ml)		Test of significance (p)
	Mean ± SD	Median (Min- Max)		Mean ± SD	Median (Min- Max)	
Sex						
Male	17.6± .9	17.2(16.14-18.19)	(U=147, P=0.154)	8.67±.5	8.7(7.9-9.4)	(U=113.5, P=0.95)
Female	18.11± .71	18.2(16.7-18.9)		8.7±.5	9.04(7.8-9.23)	
H. pylori						
Positive	17.68±.94	17.9(16.14-18.96)	(U=91.5, P=0.4)	8.72±.53	9(7.9-9.4)	(U=109.5, P=0.92)
Negative	17.9±.78	18(16.7-18.9)		8.73±.54	9(7.8-9.3)	

U; Mann-Whitney test.

SD; standard deviation, * significant (p<0.05)




Figure 2: Correlation between Pg1 and age among GC group

Table 5: Linear regression model for predictors of Pg1 and Pg 1/2 among the studied sample

Predictors	Unstandardized Coefficients B std. error		Standardized Coefficients Beta	t	Significance	95% CI
Pg1						
Constant	53.158	1.164			<0.001*	
Age	-0.131	0.017	-0.103	-7.736	<0.001*	-0.165 – -0.098
Sex ^a	0.509	0.376	0.018	1.355	0.179	-0.238 – 1.257
H. pylori ^b	-0.174	0.368	-0.006	-0.473	0.638	-0.906 – 0.558
Disease ^c	-29.354	0.395	-0.971	-74.405	<0.001*	-30.138 – -28.569
Pg ½						
Constant	1.305	0.409		3.186	0.002*	
Age	0	0.002	0.003	0.185	0.854	(-0.003 - 0.003)
Sex ^a	0.015	0.026	0.006	0.565	0.574	(-0.038- 0.068)
H. pylori ^b	-0.028	0.026	-0.012	-1.08	0.283	(-0.079 - 0.023)
Disease ^c	-0.475	0.223	-0.188	-2.126	0.036*	(-0.919 – -0.031)
Pg1	0.068	0.008	0.81	8.971	<0.001*	(0.053 - 0.083)

^A ref; Female

^B ref; negative H. pylori

^C ref; not-disease

Table 6: ROC curve analysis for Pg1 and Pg1/2 (ng/l) in diagnosing AG or GC patients

AUC	95% CI	Point of Cut off	Sensitivity (95% CI)	Specificity (95% CI)	+PV	-PV	p
1	0.960 – 1.000	≤18.96	100 (94 – 100)	100 (88.4 – 100)	100	100	<0.001*
AUC	95% CI	Point of Cut off	Sensitivity (95% CI)	Specificity (95% CI)	+PV	-PV	p
1	0.960 – 1.000	≤ 2.25	100 (94 – 100)	100 (88.4 – 100)	100	100	<0.001*

AUC: Area under the curve

+PV: positive predictive value

-PV: negative predictive value

4. Discussion

To date, it remains debatable for using Pg as a non-invasive biomarker for diagnosing AG or GC [12, 13]. In the present work, although the means of Pg 1 in AG (16.95 ± 1.12 ng/ml) and GC (17.83 ± 0.85 ng/ml) patients were comparable ($p = .098$), however, they were highly statistically significantly lower than healthy controls (47.23 ± 3.69 ng/ml) ($p < 0.001$ for both). Also, the mean of Pg 1/2 in the AG group (2.02 ± 0.08 ng/ml) was nearly equal to that in the GC group (2.05 ± 0.07 ng/ml) ($p = 0.976$), but they were highly statistically significantly lower than healthy controls (4.53 ± 0.32 ng/ml) ($p < 0.001$ for both). These results suggest a possible relationship between Pg 1 and Pg 1/2 ratio in diagnosing AG and GC.

These findings confirm those of Mansour-Ghanaei et al [10], who discovered that patients suffering GC had considerably lower Pg 1 serum levels and Pg 1/2 ratio than did healthy individuals. Additionally, Kim et al [16], found that among 95 patients, patients diagnosed with AG had significantly lower Pg serum levels and also ratio. Similar to this, Nguyen et al [17], assessed how Pg in serum can help in mild and severe AG diagnosis among the Vietnamese population. They came to the conclusion that the serum PGII lacked diagnostic significance while the Pg 1 level and Pg 1/2 ratio were found to

be significant indicators for diagnosing AG. Our findings, however, contrast from those of an Iranian study by Hosseini et al [13], which found no link between Pg 1 serum level and AG but find correlation that was statistically significant among AG and Pg 2 and Pg 1/2 ratio levels.

A correlation that was not significant statistically between Pg1 and Pg1/2 and H. pylori was noticed in the current study, whether in AG patients or GC patients. The results of this investigation, however, contradict past reports [18, 19] that suggested a substantial correlation between Pg levels and H pylori infection. According to research reported by Yuan et al [20], patients with active H. pylori infection had greater blood Pg levels and lower Pg 1/2 levels than patients without the illness. Also, Cai et al [21], observed that in patients with gastric mucosal atrophy, H. pylori-positive subjects showed considerably statistically significant higher Pg 1 and Pg 2 serum levels and a statistical significant lower P 1/2 in comparison to H. pylori-negative patients ($P 0.05$). That could be explained by the inconsistent findings of tests performed to find H pylori and the presence of additional variables that could alter the results, such as gender, BMI, and drugs taken (such as proton pump inhibitors).

Regarding the relation between AG activity and Pg1 and Pg 1/2 levels

our findings were consistent with Nguyen et al [17]. We found that in AG patients, the disease activity is related to Pg1 and Pg 1/2 where the lowest levels of Pg1 and Pg 1/2 were reported in the severe active disease. According to Nguyen et al [17], the moderate to severe AG group had serum Pg 1 levels that were lower significantly more than those of mild AG group. Similar to this, Tong et al [22], assessed Pg levels in the serum and examined the link with finding of both endoscope and histology in a prospective study of asymptomatic patients. They found that when compared to the groups with mild atrophy and no atrophy, Pg levels in the group with severe AG reduced significantly ($p < 0.01$). There is debate regarding the relationship between other variables including age and gender and pepsinogen levels. Results of a research including 6596 “healthy” participants were reported by Huang et al [23]. According to the study, pepsinogen levels rose in men and fell in women as people aged. The study revealed that values of pepsinogen diminished with age and increased more in males than females. However, Zhang et al [24] did not discover any statistically significant age- and sex-related values of P 1/2 in their investigation of 2568 healthy individuals. They did note a modest increase in Pg 1 and Pg 2 with ageing in both sexes, though.

Several studies looked at the serum Pg diagnostic value in the AG and GC diagnosis. In various investigations, the sensitivity ranges of Pgs range from 36.84% [25] to 90.91% [26] for the GC detection and from 25% [27] to 91.18% [28] to AG detection. In this study, we discovered that serum Pg has a very high diagnostic value for GC and AG. The best cut-off values for diagnosing AG or GC were PGI 18.96 and Pg 1/2 2.25, which might result in 100% sensitivity (94-100), 100% specificity (88.4-100), 100% PPV, and 100% NPV. This result appears to be consistent with those of earlier studies [8, 9, 11, 17, 22] which found that Pg 1 and Pg 1/2 have a diagnostic value in identifying AG. Additionally, this outcome was comparable to that stated by Mansour-Ghanaei et al [10], which discovered that both Pg 1 and Pg 1/2 are the only selective and sensitive for GC screening. According to Nguyen et al [17]. For the investigation of moderate and severe AG, the serum Pg 1 and Pg 1/2 ratios showed an accurate diagnostic value, with the Pg 1/2 ratio being preferable. They discovered that the optimal diagnostic AG cut-off values were (Pg 169.0) and (Pg 1/24.6), which could yield results with a final accuracy of 82.4% and sensitivity, specificity, PPV, and NPV of 73%, 83.9%, 41.5%, and 95.2% based on images of gastroscopy. The optimum cut-off values for GC diagnosis were Pg 1 63.5 and Pg 1/2 5.2, which might result in final accuracy of 72.9% and sensitivity of 49.4%, specificity of 82.1%, PPV of 52.1%, NPV of 80.5%, and 82.1% specificity. A meta-analysis involving 30,000 patients from 13 different Eastern and Western nations was carried out to evaluate the accuracy of Pg in AG and GC diagnosis [9], Huang et al. results showed that [9] Pg 1 had a 69% sensitivity and 73% specificity for diagnosis of intestinal GC and 69% sensitivity and 88% specificity for diagnosis of AG. Although the authors acknowledged it as a limitation, the research heterogeneity in respect of diagnostic methodologies and the various cut-off values for these procedures. Blood

Pg levels were used in a study by Broutet et al [29], on 284 patients suffering dyspeptic related complaints in 14 European countries to assess the severity of multifocal AG. They claimed that the only pre-cancerous stomach lesions biomarker that may be used as a screening test is the Pg 1/2 ratio. The following outcomes were reported in relation to the Pg 1/2: having a 5.6 cut-off point, and 65.0% sensitivity and 77.9% specificity. Since we evaluated a cut-off value of pepsinogen levels ranging from mild to moderate and severe AG up to GC, our study's Pg 1 and Pg 1/2 cut-offs were lower than those reported in the literature. As a result, as compared to what is reported in the literature, Pg 1 and Pg 1/2 have higher sensitivity and specificity for diagnosing AG and GC. Some researchers have discovered outcomes that are not significant or are weak, in contrast to our findings. One of these is a study by Ricci et al [30]. which found that Pg 1 and Pg 1/2 cannot distinguish between patients with and without antrum-predominant AG. Similarly, Colarossi et al [31]. showed that none of the biomarkers could distinguish between patients who had atrophy and those who did not. Age, *H. pylori* infection, AG activity, the GC cardia/non-cardia nature, and AG alone or combined with metaplasia that was intestinally involved, are some of the variables that may contribute to these variances. These variables can also change the serum pepsinogens levels. Additionally, the great variation in Pg serum testing methods makes it challenging to interpret the data. The most used technique is ELISA, but some researchers also utilize immunoturbidimetry, radioimmunoassay, chemiluminescent assay, and the latex agglutination test [32].

This study only used a limited sample size, therefore that is one of its limitations. Serum pepsinogen in AG and GC were not separately evaluated for their diagnostic value (sensitivity and specificity).

5. Conclusion

Serum Pg demonstrated a very high diagnostic value for the diagnosis of AG and GC. In which it was discovered that the Pg 1/2 ratio and Pg 1 level were helpful biomarkers for the diagnosis of patients with AG and GC.

References

1. Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies. *Int J Mol Sci.* 2020; 21(11).
2. Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. *Prz Gastroenterol.* 2019; 14(1): 26-38.
3. Waddingham W, Nieuwenburg SAV, Carlson S, Rodriguez-Justo M, Spaander M, Kuipers EJ, et al. Recent advances in the detection and management of early gastric cancer and its precursors. *Frontline Gastroenterol.* 2021; 12(4): 322-31.
4. Lahner E, Esposito G, Galli G, Annibale B. Atrophic gastritis and pre-malignant gastric lesions. *Transl Gastrointest Cancer.* 2015; 4(4): 272-81.
5. Cheung DY. Atrophic Gastritis Increases the Risk of Gastric Cancer in Asymptomatic Population in Korea. *Gut Liver.* 2017; 11(5): 575-6.

6. Agkoc M, Dursun H, Albayrak F, Yilmaz O, Kiziltunc A, Yilmaz A, et al. Usefulness of serum pepsinogen levels as a screening test for atrophic gastritis and gastric cancer. *Eurasian J Med.* 2010; 42(1): 15-8.
7. Su W, Zhou B, Qin G, Chen Z, Geng X, Chen X, et al. Low PG I/II ratio as a marker of atrophic gastritis: Association with nutritional and metabolic status in healthy people. *Medicine (Baltimore).* 2018; 97(20): e10820.
8. Miftahussurur M, Waskito LA, Aftab H, Vilaichone RK, Subsomwong P, Nusi IA, et al. Serum pepsinogens as a gastric cancer and gastritis biomarker in South and Southeast Asian populations. *PLoS One.* 2020; 15(4): e0230064.
9. Huang YK, Yu JC, Kang WM, Ma ZQ, Ye X, Tian SB, et al. Significance of Serum Pepsinogens as a Biomarker for Gastric Cancer and Atrophic Gastritis Screening: A Systematic Review and Meta-Analysis. *PLoS One.* 2015; 10(11): e0142080.
10. Mansour-Ghanaei F, Joukar F, Baghaee M, Sepehrimanesh M, Hojati A. Only serum pepsinogen I and pepsinogen I/II ratio are specific and sensitive biomarkers for screening of gastric cancer. *Biomol Concepts.* 2019; 10(1): 82-90.
11. Bang CS, Lee JJ, Baik GH. Prediction of Chronic Atrophic Gastritis and Gastric Neoplasms by Serum Pepsinogen Assay: A Systematic Review and Meta-Analysis of Diagnostic Test Accuracy. *J Clin Med.* 2019; 8(5).
12. Leja M, Camargo MC, Polaka I, Isajevs S, Liepniece-Karele I, Janciauskas D, et al. Detection of gastric atrophy by circulating pepsinogens: A comparison of three assays. *Helicobacter.* 2017; 22(4).
13. Hosseini M, Amoueian S, Attaranzadeh A, Montazer M, Soltani G, Asadollahi K, et al. Serum gastrin 17, pepsinogen I and pepsinogen II in atrophic gastritis patients living in North-East of Iran. *J Res Med Sci.* 2013; 18(3): 225-9.
14. Terasawa T, Nishida H, Kato K, Miyashiro I, Yoshikawa T, Takaku R, et al. Prediction of gastric cancer development by serum pepsinogen test and *Helicobacter pylori* seropositivity in Eastern Asians: a systematic review and meta-analysis. *PLoS One.* 2014; 9(10): e109783.
15. Stolte M, Meining A. The updated Sydney system: classification and grading of gastritis as the basis of diagnosis and treatment. *Can J Gastroenterol.* 2001; 15(9): 591-8.
16. Kim EH, Kang H, Park CH, Choi HS, Jung DH, Chung H, et al. The optimal serum pepsinogen cut-off value for predicting histologically confirmed atrophic gastritis. *Dig Liver Dis.* 2015; 47(8): 663-8.
17. Nguyen CL, Dao TT, Phi T-TN, Nguyen TP, Pham VT, Vu TK. Serum pepsinogen: A potential non-invasive screening method for moderate and severe atrophic gastritis among an asian population. *Annals of Medicine and Surgery.* 2022; 78: 103844.
18. Tu H, Sun L, Dong X, Gong Y, Xu Q, Jing J, et al. Serum anti-*Helicobacter pylori* immunoglobulin G titer correlates with grade of histological gastritis, mucosal bacterial density, and levels of serum biomarkers. *Scand J Gastroenterol.* 2014; 49(3): 259-66.
19. Shan JH, Bai XJ, Han LL, Yuan Y, Sun XF. Changes with aging in gastric biomarkers levels and in biochemical factors associated with *Helicobacter pylori* infection in asymptomatic Chinese population. *World J Gastroenterol.* 2017; 23(32): 5945-53.
20. Yuan L, Zhao JB, Zhou YL, Qi YB, Guo QY, Zhang HH, et al. Type I and type II *Helicobacter pylori* infection status and their impact on gastrin and pepsinogen level in a gastric cancer prevalent area. *World J Gastroenterol.* 2020; 26(25): 3673-85.
21. Cai HL, Tong YL. Association of serum pepsinogen with degree of gastric mucosal atrophy in an asymptomatic population. *World J Clin Cases.* 2021; 9(31): 9431-9.
22. Tong Y, Wu Y, Song Z, Yu Y, Yu X. The potential value of serum pepsinogen for the diagnosis of atrophic gastritis among the health check-up populations in China: a diagnostic clinical research. *BMC Gastroenterol.* 2017; 17(1): 88.
23. Huang RG, Xiao HL, Zhou B, Song XH, Zhang J, Wang CM, et al. Serum Pepsinogen Levels Are Correlated With Age, Sex and the Level of *Helicobacter pylori* Infection in Healthy Individuals. *Am J Med Sci.* 2016; 352(5): 481-6.
24. Zhang L, Niu Y, Lv YJ, Wu LF, Hu QL, Huang R, et al. Preliminary Study on Reference Interval of Serum Pepsinogen in Healthy Subjects. *Patient Prefer Adherence.* 2021; 15: 2725-30.
25. Mizuno S, Kobayashi M, Tomita S, Miki I, Masuda A, Onoyama M, et al. Validation of the pepsinogen test method for gastric cancer screening using a follow-up study. *Gastric Cancer.* 2009; 12(3): 158-63.
26. Huang Y, Cheng W, Gao N, Ye N, Qian Y. The diagnostic value of serum pepsinogen I, II for gastric cancer and precancerous lesions of gastric cancer detection. *Chinese Journal of Internal Medicine.* 2013; 52(4): 332-3.
27. Sitas F, Smallwood R, Jewell D, Millard PR, Newell DG, Meuwissen SG, et al. Serum anti-*Helicobacter pylori* IgG antibodies and pepsinogens A and C as serological markers of chronic atrophic gastritis. *Cancer Epidemiol Biomarkers Prev.* 1993; 2(2): 119-23.
28. Sierra R, Une C, Ramirez V, González MI, Ramirez JA, de Mascarel A, et al. Association of serum pepsinogen with atrophic body gastritis in Costa Rica. *Clin Exp Med.* 2006; 6(2): 72-8.
29. Broutet N, Plebani M, Sakarovitch C, Sipponen P, Mégraud F. Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspeptics. *Br J Cancer.* 2003; 88(8): 1239-47.
30. Ricci C, Vakil N, Rugge M, Gatta L, Perna F, Osborn JF, et al. Serological markers for gastric atrophy in asymptomatic patients infected with *Helicobacter pylori*. *Am J Gastroenterol.* 2004; 99(10): 1910-5.
31. Colarossi A, Inga R, Prochazka R, Reyes U, Bussalleu A, Barúa RL. [Pepsinogen and gastrin in the noninvasive diagnosis of gastric atrophy. A case-control study in Peruvian population]. *Rev Gastroenterol Peru.* 2011; 31(2): 110-5.
32. Lomba-Viana R, Dinis-Ribeiro M, Fonseca F, Vieira AS, Bento MJ, Lomba-Viana H. Serum pepsinogen test for early detection of gastric cancer in a European country. *Eur J Gastroenterol Hepatol.* 2012; 24(1): 37-41.